DiscoveryProbe™ FDA-approved Drug Library: Enabling High-Content Drug Screening and Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 bioactive compounds approved by major global regulatory agencies, supporting reproducible high-throughput screening (HTS) and high-content screening (HCS) workflows (APExBIO product page). Each compound is supplied as a 10 mM DMSO solution, stable for up to 24 months at -80°C. The library has been validated in studies identifying synergistic drug effects and mechanistic pathways, such as ChaC1-mediated auranofin and proteasome inhibitor synergy in hepatocellular carcinoma (Zheng et al., 2023). The collection enables drug repositioning, target validation, and pathway analysis for diverse disease models (related article). APExBIO’s curation ensures regulatory traceability and research-grade quality for translational applications.

Biological Rationale

The DiscoveryProbe™ FDA-approved Drug Library is designed to address key challenges in early-stage drug discovery and translational research. Modern biomedical research relies on access to well-characterized, clinically validated molecules for hypothesis-driven screening. FDA-approved compound libraries permit rapid exploration of drug repurposing opportunities, leveraging established safety and pharmacokinetic profiles (Zheng et al., 2023). Since each compound has undergone regulatory review, researchers can focus on efficacy, mechanism of action, and new targets, reducing bottlenecks in preclinical development. The library’s spectrum encompasses enzyme inhibitors, receptor modulators, ion channel effectors, and pathway regulators, supporting applications in cancer, neurodegenerative disease, infectious disease, and rare disease models (see FK228.org article, which this review extends by focusing on mechanistic and workflow integration aspects).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library covers a wide range of pharmacological activities. Compounds act as:

• Receptor agonists/antagonists: Modulate neurotransmitter, hormone, and growth factor pathways (e.g., metformin, doxorubicin, atorvastatin).
• Enzyme inhibitors: Target kinases, proteases, and metabolic enzymes (e.g., bortezomib, an FDA-approved proteasome inhibitor).
• Ion channel modulators: Influence ionic flux, impacting cardiac, neuronal, and muscular physiology.
• Signal pathway regulators: Affect pathways such as PI3K/Akt, MAPK, and oxidative stress (e.g., auranofin’s role in glutathione metabolism).

Each compound is supplied as a 10 mM solution in DMSO, allowing direct assay integration. The library’s diversity enables both phenotypic screens (detecting observable biological effects) and target-based approaches (testing defined molecular interactions). The curated collection ensures traceability to regulatory-approved reference standards (product page).

Evidence & Benchmarks

• ChaC1-based screening with the DiscoveryProbe™ FDA-approved Drug Library identified a synergistic lethal effect of auranofin and proteasome inhibitors in hepatocellular carcinoma cells (Zheng et al., 2023).
• Auranofin (5–10 µM, 24–48 hours, in Huh7 cells) enhanced cell death when ChaC1 expression was upregulated, demonstrating glutathione-depletion-dependent cytotoxicity (Fig. 1B).
• Proteasome inhibitors (bortezomib, ixazomib, delanzomib; 10–50 nM, 24–48 hours) induced ChaC1 expression in an ATF4-dependent manner, suggesting a mechanistic link between proteasome inhibition and oxidative stress response (Results section).
• Combined treatment with auranofin and proteasome inhibitors led to upregulation of cell-death-associated genes (DEDD2, DDIT4), and this effect was blocked by antioxidants (NAC) but not by apoptosis or necroptosis inhibitors (Fig. 3, Table 1).
• The DiscoveryProbe™ library has been used in screens for viral protease inhibitors and pathway regulators, accelerating antiviral and mechanistic discovery (see GSKChem.com article; this article updates with new oncology evidence).
• Compound format (10 mM, DMSO) and stability (12–24 months at -20°C to -80°C) ensure reproducibility in multi-site screening projects (APExBIO).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports multiple research paradigms:

• Drug repositioning screening: Identifying new indications for approved drugs, reducing development time and cost (see SB-715992.com; this review clarifies mechanistic and parameter-specific details).
• Pharmacological target identification: Uncovering molecular targets and pathways relevant to disease phenotypes.
• Cancer research drug screening: Rapid profiling of cytotoxicity, synergy, and resistance mechanisms in cancer cell lines.
• Neurodegenerative disease drug discovery: Screening for modulators of signaling pathways implicated in neuroprotection and neurotoxicity.
• Signal pathway regulation: Dissecting complex signaling cascades using well-characterized modulators.
• Enzyme inhibitor screening: Targeting kinases, proteases, and metabolic enzymes.

Common Pitfalls or Misconceptions

• The library does not include investigational new drugs or compounds lacking regulatory approval.
• It is not a substitute for in vivo pharmacokinetic or toxicological evaluation; in vitro results require further validation.
• Compound concentrations and solvent compatibility should be optimized for each assay—DMSO tolerance may vary across cell types.
• Not all mechanisms of action are exhaustively annotated; users should consult primary literature for compound-specific details.
• Some rare or region-specific approvals may be underrepresented compared to global FDA, EMA, HMA, CFDA, or PMDA standards.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is engineered for seamless integration into high-throughput and high-content screening platforms. Key workflow features include:

• Compounds supplied as 10 mM DMSO solutions in 96-well plates, deep well plates, or 2D-barcoded tubes for flexible assay setup.
• Storage at -20°C (12 months) or -80°C (24 months) preserves compound integrity; shipments are on blue ice for evaluation samples and by request for larger batches.
• Ready-to-use formulation eliminates the need for compound dissolution or aliquoting, reducing variability.
• Compatible with cell-based, biochemical, and target engagement assays.
• Barcode tracking supports automation and sample traceability in multi-site and multi-parameter screens.
• The L1021 kit facilitates parallel screening for both phenotypic and mechanistic endpoints, including pathway activation, cytotoxicity, and target engagement.

For further details on format options and integration, refer to the DiscoveryProbe™ FDA-approved Drug Library specification page.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO offers a rigorously curated, regulatory-grade resource for next-generation drug screening. Its broad coverage of approved pharmacological agents enables translational researchers to accelerate target identification, drug repositioning, and pathway elucidation across oncology, neurodegeneration, and infectious disease. By delivering compounds in ready-to-screen formats with verifiable regulatory lineage, the library bridges discovery and clinical translation. Future applications will benefit from integration with multi-omic readouts and advanced phenotypic profiling. For expanded use cases, see DiscoveryProbe FDA-approved Drug Library: Accelerate Drug..., which this review updates with mechanistic and workflow integration benchmarks.